JONEXA UP

JONEXA UP is an injectable hydrogel:
- Sterile, apyrogenic and with a low level of endotoxins.
- It reduces pain and increases the functionality of the affected joint.
- Provides a lubricating and shock-absorbing effect on the joint
- interested.
- It improves the patient's quality of life.

- ABIOGEN PHARMA
- NAME: JONEXA UP
- COMPOSITION: Sodium hyaluronate cross-linked 20 ml, Disodium phosphate dodecahydrate 0.6 ml, Sodium dihydrogen phosphate dihydrate 0.05 ml, Sodium chloride 8 ml, Water for Injectable Preparation q.v.
- PRESENTATION: 1 x 4.4 ml.
- NEEDLES: 19G needles are suggested.
- INDICATIONS: Indicated for joint viscosupplementation, useful for reducing pain and improving knee mobility in cases of arthrosis or cartilage degeneration.
- INJECTION DEPTH: Intra-articular injection.
- DURATION: The action of viscosupplement can contribute to the improvement of joint symptoms for several months, with a duration of effect of up to approximately 6 months, varying depending on the patient's clinical condition and the level of joint degeneration.
- USE: Strict medical use.

- Syringe: 1 x 4.4 ml.

Knee.

Sodium hyaluronate cross-linked 20 ml, Disodium phosphate dodecahydrate 0.6 ml, Sodium dihydrogen phosphate dihydrate 0.05 ml, Sodium chloride 8 ml, Water for Injectable Preparation q.v.

- JONEXA UP must be rigorously injected into the intra-articular space following aseptic injection procedures.
- JONEXA UP must be administered with sterile Luer-lock needles.
- Do not inject into a blood vessel or surrounding tissue. To avoid pain after injection, it is recommended to keep the local injection site immobile.
- The product must not be used if the packaging is damaged or broken.
- The product must not be used after the expiry date.
- The product is for single use only. Do not reuse; risk of infection.
- Do not re-sterilise; re-sterilisation may affect the physical and chemical properties of the product and compromise its efficacy and safety.
- The used syringe and needle must be disposed of in an appropriate container.
- Keep out of reach of children.

- Do not administer JONEXA UP to patients with known hypersensitivity (allergy) to hyaluronic acid and/or other components of the product.
- Do not administer JONEXA UP to patients with acute or chronic skin disorders or inflammatory and/or infectious skin problems.
- JONEXA UP should not be administered to patients with coagulation disorders and/or on anticoagulant medication.
- JONEXA UP should not be administered to pregnant or breastfeeding women.
- JONEXA UP should not be administered to children.
- The use of JONEXA UP in any joint other than the knee and for other conditions has not been studied.

JONEXA UP should be injected inside the joint into the synovial space of the knee, as a viscosupplementation medium for synovial fluid, when fluid viscosity is reduced due to the osteoarthritis process, in patients who have not responded adequately to conservative non-pharmacological therapy and simple analgesics.